Clinical Trial Update: A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase II trial of Abraxane (nab-paclitaxel) given weekly as a single-agent therapy in first-line metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)

Snippet

Sponsor: Veeda Oncology | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED